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Pharmaceuticals  that  suppress  HIV-­1  viremia  preserve  CD4+  T  cells  and  prevent  AIDS.  
Nonetheless,   HIV-­1   infected   people   taking   these   drugs   have   chronic   inflammation  
attributable   to  persistent  disruption  of   intestinal  barrier   function  with   increased  rates  of  
cardiovascular   mortality.   To   better   understand   the   etiology   of   this   inflammation   we  
examined   the   effect   of   HIV-­1   infection   on   innate   lymphoid   cells   (ILCs).   These   innate  
immune  counterparts  of  T  cells   lack  clonotypic  antigen  receptors,  classify  according  to  
signature   transcription   factors   and   cytokines,   and   maintain   homeostasis   in   inflamed  
tissues.  ILCs  have  been  defined,  in  part,  by  the  IL-­7Rα,  CD127.  Here  we  report  that  the  
vast  majority  of  type  1  and  3  ILCs  in  human  adult  and  placental  cord  blood  are  in  fact  
CD127-­,  as  are  colon  lamina  propria  ILC1s  and  many  ILC3s.  Among  ILCs,  CD127-­ILC1s  
were   the   major   producer   of   inflammatory   cytokines.   In   contrast   to   CD127+ILC3s,  
CD127-­ILC3s  did  not  produce  IL-­22,  a  cytokine  that  maintains  epithelial  barrier  function.  
In   HIV-­1+   people   taking   antivirals   that   preserve   CD4+   T   cells,   CD127-­ILC1s   and   all  
homeostatic   cytokine-­producing   CD127+ILCs   were   decreased   in   blood   and   colon.  
Common   γ-­chain   cytokines   that   are   reported   to   be   elevated   in   response   to   HIV-­1  
infection   caused   JAK3-­dependent   downregulation   of   CD127   and   converted   CD127-­
ILC1s   into  NK  cells  with  heightened  cytolytic  activity.  Consistent  with  the  recent  report  
that  human  blood  CD117+ILCs  give   rise   to  both   ILC1s  and  NK  cells,   pseudotemporal  
clustering   of   transcriptomes   from   thousands   of   individual   cells   identified   a  
developmental   trajectory   from  CD127-­ILC1s   to  memory  NK   cells   that   was   defined   by  
WNT-­transcription   factor   TCF7.   WNT   inhibition   prevented   the   cytokine-­induced  
transition  of  CD127-­ILC1  cells  into  memory  NK  cells.  In  HIV-­1+  people,  effector  NK  cells  
and   TCF7+   memory   NK   cells   were   elevated,   concomitant   with   reduction   in   CD127-­
ILC1s.   These   studies   describe   previously   overlooked   human   ILC   subsets   that   are  
significant   in  number  and  function,   identify  profound  abnormalities  in  homeostatic  ILCs  
that   likely   contribute   to   ongoing   inflammation   in   HIV-­1   infection   despite   control   of  
viremia,   provide   explanation   for   increased   memory   NK   cells   in   HIV-­1   infection,   and  
reveal  functional  plasticity  of  ILCs.  
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INTRODUCTION  
HIV-­1   infection   is   lifelong   and   no   treatments   yet   available   reliably   eliminate   the   virus  
from  infected  people  (Margolis  et  al.,  2016).  Given  uninterrupted  access  to  antiviral  drug  
combinations   that   suppress  HIV-­1  viremia   it   is  possible   to  preserve  CD4+  T  cells  and  
prevent  progression   to  AIDS   (Günthard  et  al.,   2016;;  Taieb  et  al.,   2017;;  Tucker  et  al.,  
2017).   Nonetheless,   infected   individuals   on   these   antiviral   therapies   have   chronic  
inflammation   with   increased   rates   of   cardiovascular   mortality   (Freiberg   et   al.,   2013;;  
Sinha   et   al.,   2016).   This   pathology   has   been   attributed   to   permanent   disruption   of  
cellular   networks   that   maintain   the   integrity   of   the   intestinal   epithelium   and   limit   the  
intestinal  microbiome  (Brenchley  et  al.,  2006;;  Deeks  et  al.,  2013;;  Klatt  et  al.,  2012).  
  
Innate   lymphoid   cells   (ILCs)   are   counterparts   of   T   cells   that   lack   clonotypic   antigen  
receptors   or   other   lineage-­defining   cell   surface  markers   (Hazenberg   and  Spits,   2014;;  
Spits   et   al.,   2013).   Like   T   cells,   they   are   classified   into   subsets   according   to   the  
signature   transcription   factors   that   they   express   and   the   effector   cytokines   that   they  
produce  (Serafini  et  al.,  2015).  Among  the  many  subsets  of  ILCs  are  natural  killer  (NK)  
cells   that  are  capable  of   lysing   tumor  cells  and  virus-­infected  cells   (Spits  et  al.,  2016;;  
Vivier  et  al.,  2008).  ILCs  carry  out  a  large  range  of  biological  functions,  including  roles  in  
host   defense  against   pathogens  and  maintenance  of   homeostasis   in   inflamed   tissues  
(Artis  and  Spits,  2015;;  Klose  and  Artis,  2016;;  Spits  et  al.,  2016).  
  
ILCs  have  been  defined  as  Lin-­CD127+  cells  that  are  divided  into  three  main  subsets  -­  
ILC1s,   ILC2s,   and   ILC3s   -­   based   on   expression   of   TBX21,   GATA3,   or   RORγT,  
respectively   (Spits   et   al.,   2013;;  Walker   et   al.,   2013).  Mouse  NK   cells   are   Lin-­Tbx21+,  
but,  unlike  ILC1s,  they  are  CD127-­  and  Eomes+,  and  they  develop  independently  of  the  
ID2+  common  helper-­like  ILC  progenitor  (Klose  et  al.,  2014).  However,  human  NK  cells  
and   ILCs   are   capable   of   differentiating   from   a   common   Lin-­CD117+   cell   (Lim   et   al.,  
2017),  and  several  observations  challenge   the  use  of  CD127  or  Eomes   to  distinguish  
ILC1s   and  NK   cells.   CD127   is   not   required   for   development   of   all   ILC   subtypes;;   the  
number  of  lymphoid-­tissue-­inducer  (LTi)  cells,  a  subset  of  ILC3s,  is  normal  in  the  blood  
and  spleen  of  CD127-­/-­  or  IL-­7-­/-­  mice  (Luther  et  al.,  2003;;  Schmutz  et  al.,  2009).  Eomes  
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is  not   required   for   the   formation  of  NK  cells,   its  expression  can  be   induced   in  Eomes-­
Tbx21+NK   cells   (Gordon   et   al.,   2012)   or   repressed   by   TGF-­β   (Cortez   et   al.,   2016).  
Given   the  uncertain   significance  of  CD127  and  EOMES,   several   human  studies  have  
used  CD94   to   distinguish  NK   cells   from   ILCs   (Björklund   et   al.,   2016;;  Hazenberg   and  
Spits,   2014),   and   single   cell   RNA-­Seq   has   shown   that   the   transcriptional   profile   of  
CD94+NKG2A+NK  cells   is  distinct  from  CD94-­/NKG2A-­ILC1s  and  other  ILCs  (Björklund  
et  al.,  2016).  
  
Several  observations  suggest  that  ILCs  play  roles  in  HIV-­1-­associated  pathology  and  in  
anti-­HIV-­1  immunity.  Blood  ILCs  are  irreversibly  depleted  by  HIV-­1  if  antiviral  therapy  is  
not   started   within   a   few   weeks   of   acute   infection   (Kløverpris   et   al.,   2016).   The  
contribution  of  ILC  deficiency  to  HIV-­1-­associated  chronic  inflammation  remains  unclear  
since   abnormalities   in   homeostatic   colon   lamina   propria   ILCs   were   not   observed  
(Kløverpris  et  al.,  2016).  NK  cells  kill  HIV-­1-­infected  cells   (Alter  et  al.,  2011)  and  SIV-­
infected   macaques   have   NK   cells   with   apparent   antigen-­specific   memory   responses  
(Reeves  et  al.,  2015).  The  clinical  significance  of  NK  cells  for  HIV-­1  is  supported  by  the  
fact   that   control   of  HIV-­1   viremia   is   associated  with  HLA-­C   variants   that   interact  with  
killer  cell  immunoglobulin-­like  receptor  (KIR)  proteins  on  the  surface  of  NK  cells  (Lin  et  
al.,  2016b).  
  
The  experiments  presented  here  examined   the  criteria   that  are  used   to  define  human  
ILCs.  Consistent  with  the  finding  that  all  human  ILCs,  including  NK  cells,  can  be  derived  
from  a  common  Lin-­CD117+  progenitor  (Lim  et  al.,  2017),  significant  deviation  from  the  
established   markers   for   mouse   ILCs   was   observed,   setting   the   stage   for   detailed  
examination  of  the  specific  ILC  subpopulations  in  human  blood  and  colon  lamina  propria  
that  are  perturbed  by  HIV-­1.  Explanation  for  those  abnormalities  was  sought,  given  that  
these  cells  lack  requisite  HIV-­1  entry  receptors  and  cannot  be  directly  infected  by  HIV-­1.  
What  emerges  is  a  greater  understanding  of  the  role  that  ILCs  play  in  HIV-­1-­associated  
pathology  and  immunity,  and  of  ILC  plasticity  more  generally.  
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RESULTS  
Major  Populations  of  TBX21+  and  RORγT+  ILCs  are  CD127-­  
  
To   identify   ILCs   from   among   human   peripheral   blood   mononuclear   cells   (PBMCs),  
eleven   cell   surface   proteins   were   used   to   exclude   cells   from   other   developmental  
lineages  (Figures  1A,  S1A,  and  S1B).  Given   that  CD127  and  EOMES  are  not   reliable  
markers  to  distinguish  human  TBX21+ILC1s  from  NK  cells  (Cortez  et  al.,  2016;;  Gordon  
et  al.,   2012;;  Lim  et  al.,   2017;;  Luther  et  al.,   2003;;  Schmutz  et  al.,   2009),  and   that   the  
transcriptional  profile  of  human  CD94+NK  cells   is  distinct   from  that  of  CD94-­ILC1s  and  
other  ILCs  (Björklund  et  al.,  2016),  and  that  several  human  ILC  studies  have  used  CD94  
to  exclude  NK  cells  (Björklund  et  al.,  2016;;  Hazenberg  and  Spits,  2014;;  Kløverpris  et  al.,  
2016),   we   used   anti-­CD94   to   exclude  NK   cells   from   our   ILC   population   (Figures   1A,  
S1A,  and  S1B).  The  remaining  lineage  negative  (Lin-­)  cells  were  then  gated  on  TBX21  
to   define   ILC1s,  CRTH2   for   ILC2s,   and  RORγT   for   ILC3s   (Spits   et   al.,   2013)   (Figure  
1B).  No  Lin-­TBX21+RORγT+  double-­positive  NKp44+ILC3s  (Hazenberg  and  Spits,  2014)  
were  detected  (Figures  S1C  and  S2A),  so  ILC1  cells  accounted  for  all  Lin-­TBX21+  cells.  
  
Since   CD127-­positivity   has   been   considered   a   defining   characteristic   of   human   ILCs  
(Björklund  et  al.,  2016;;  Hazenberg  and  Spits,  2014;;  Ishizuka  et  al.,  2016;;  Kløverpris  et  
al.,   2016)   it   was   surprising   that   CD127-­TBX21+ILC1s   and  CD127-­RORγT+ILC3s  were  
>100-­fold   more   abundant   than   their   CD127+   counterparts   (Figures   1B-­1D   and   S2A-­
S2C).  CRTH2+ILC2s  in  the  blood,  though,  were  nearly  all  CD127+  (Figure  1B).  Analysis  
of  eighteen  proteins  that  had  previously  been  reported  in  murine  or  human  ILCs  (Eberl  
et  al.,  2015;;  Hazenberg  and  Spits,  2014;;  Spits  et  al.,  2013)  demonstrated  that  CD127-­
ILCs  are  indeed  a  population  that  is  distinct  from  CD127+ILCs  (Figure  S2D).  As  was  the  
case   in   adult   peripheral   blood,   CD127-­TBX21+ILC1s   and   CD127-­RORγT+ILC3s   were  
similarly  abundant  among  umbilical  cord  blood  mononuclear  cells  (Figures  1E,  1G,  and  
1H).  
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To  determine  if  the  high  percentage  of  CD127-­ILCs  was  unique  to  blood,  human  colon  
lamina   propria   lymphoid   cells   were   isolated   from   biopsies   obtained   at   screening  
colonoscopy.  The  majority  of  human  colon  lamina  propria  ILC1s  were  CD127-­,  as  were  
a  significant   fraction  of   ILC3s   (Figures  1F,  1I,   and  1J).  Many  human  blood  and  colon  
lamina  propria  ILCs,  then,  form  distinct  CD127-­  populations.  
    
Among   Blood   ILCs,   CD127-­ILC1s   Are   the   Main   Producers   of   Inflammatory  
Cytokines,  and  CD127-­ILC3s  Do  Not  Make  the  Homeostatic  Cytokine  IL-­22  
ILCs  influence  biological  processes  via  production  of  cytokines  (Artis  and  Spits,  2015).  
Among   human   blood   ILCs,   CD127-­TBX21+ILC1s   were   the   main   producers   of   IFN-­γ,  
GM-­CSF,  or  TNF-­α  (Figures  1K,  1L,  S2E,  and  S2F).  This  was  in  contrast  to  the  mouse  
where   ILC3s   are   the  main   ILC   subtype   producing  GM-­CSF   (Mortha   et   al.,   2014).   As  
expected,   IL-­13  was   produced   by  CD127+ILC2s   (Figure   1M  and  S2F).   IL-­22  was   not  
detected  in  blood  ILC3s  (Figure  S2F),  most  of  which  were  CD127-­  (Figures  1B,  1D).  IL-­
22   was   detected   in   lamina   propria   ILC3s   (Figure   1M),   most   of   which   were   CD127+  
(Figure  1F).  These  results  indicate  that  IL-­22  is  only  produced  by  those  ILC3s  that  are  
CD127+.  
    
CD127+ILCs   and   CD127-­ILC1s   Are   Reduced   in   the   Blood   and   Colon   Lamina  
Propria  of  HIV-­1+  People  
To  determine  if  CD127-­  or  CD127+ILCs  are  perturbed  by  HIV-­1  infection,  PBMCs  from  
people  with   chronic  HIV-­1   infection  were   examined   (Table  S1).   All  CD127+ILCs  were  
decreased   in   the   blood   of   people   with   HIV-­1   infection   (Figures   2A,   2B,   2D,   2G,   and  
S3A),  including  CD127+ILC3s  (Figure  2E).  CD127-­ILC1s  were  also  reduced  in  the  blood  
of   HIV-­1+   individuals   (Figures   2C,   2F,   and   S3B),   though   CD127-­ILC3s   were   not  
decreased   (Figures   2E   and   2H).   The   abnormalities   in   ILCs   were   significant   (p<0.01)  
whether   all  HIV-­1+   samples  were   grouped   together   (Figures   2B,   2F,   and   2G)   or   they  
were  stratified  based  on  either  viremia  or  CD4  count  (Figures  S3C-­S3H).  
  
CD127+ILCs  were   also   decreased  among   lamina  propria   lymphoid   cells   isolated   from  
the   colon   of   HIV-­1+   individuals,   despite   anti-­HIV-­1   therapy   with   undetectable   viremia  
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and  normal  numbers  of  lamina  propria  CD4+T  cells  (Figures  2I,  2J,  and  S3I;;  Table  S1).  
The  majority  of  colon  lamina  propria  ILC3s  from  HIV-­1-­  people  were  CD127+  and  these  
cells   were   decreased   upon   HIV-­1   infection   (Figures   2I   and   2K).   The   effect   of   this  
abnormality   would   be   expected   to   deprive   the   intestinal   epithelium   of   homeostatic  
cytokines   such   as   IL-­22   (Figures   1M).   This   would   disrupt   the   integrity   of   the   colon  
epithelium   and   offer   explanation   for   ongoing   inflammation   associated   with   HIV-­1  
infection   (Deeks  et   al.,   2013)   (Figure  2L).  Consistent  with   the  observation   in  PBMCs,  
the   frequency   of   colon   CD127-­ILC3s   did   not   decrease   as   a   result   of   HIV-­1   infection  
(Figure  S3J).  
    
Cytokines   that   Use   the   Common   γ   Chain   Receptor   Regulate   the   Plasticity   of  
CD127+ILCs  via  JAK3  
To   determine   whether   the   decrease   in   CD127+ILCs   associated   with   HIV-­1   infection  
might  be  a  consequence  of  systemic  elevation   in  cytokines  or  chemokines   (Kacani  et  
al.,  1997;;  Roberts  et  al.,  2010;;  Shebl  et  al.,  2012;;  Stacey  et  al.,  2009;;  Swaminathan  et  
al.,  2016),  or  of  microbial  contents  leaking  across  the  intestinal  epithelium  (Brenchley  et  
al.,   2006;;   Deeks   et   al.,   2013),   or   of   inflammatory   markers   such   as   the   tryptophan-­
metabolite  kynurinine   (Favre  et  al.,  2010),  PBMCs  and  colon   lamina  propria   lymphoid  
cells   were   stimulated   in   vitro   and   monitored   by   flow   cytometry.   The   percentage   of  
CD127+ILCs   was   decreased   by   either   PMA   and   ionomycin,   the   ILC1   stimulating  
cytokines   IL-­12   and   IL-­15   (Figures   3A,   3B   and   S4A),   or   IFN-­β   (Figure   S4B).   No  
significant   change   was   observed   after   exposure   to   any   of   16   additional   cytokines,  
chemokines,  TLR  agonists,  bacterial  products,  or  kynurinine  (Figures  3A,  3B,  and  S4B-­
S4F).  
  
HIV-­1   infection   is   associated   with   systemic   elevation   of   cytokines   that   target   the  
common  γ  chain  receptor  (Kacani  et  al.,  1997;;  Roberts  et  al.,  2010;;  Shebl  et  al.,  2012;;  
Stacey   et   al.,   2009;;   Swaminathan   et   al.,   2016).   Given   that   IL-­15   downregulated  
CD127+ILCs   (Figures  3A  and  3B),   the  effect   of   other   common  γ   chain   cytokines  was  
tested.   IL-­2,   IL-­4,   IL-­7,   and   IL-­15,   but   not   IL-­9   or   IL-­21,   down-­regulated   CD127+ILCs  
(Figures  3C  and  S4G).  That  the  CD127-­ILCs  derive  from  CD127+ILCs  in  our  assay  was  
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shown   by   tracking   CD25,   a   protein   found   on   CD127+ILCs   (Figures   S2D   and   3D).   A  
JAK3   inhibitor,   CP-­690550,   prevented   CD127   downregulation   by   IL-­7   or   by   IL-­15  
(Figure  3E),  consistent  with  these  cytokines  signaling  via  the  common  γ  chain  (Leonard  
and  O’Shea,  1998;;  Suzuki  et  al.,  2000).  JAK1/2  inhibitor  ruxolitinib,  and  MTOR-­inhibitor  
rapamycin,  did  not  have   this  effect   (Figures  3E  and  S4H).  These   results   indicate   that  
JAK3   signaling   in   response   to   systemic   elevation   of   common   γ   chain   cytokines   likely  
decreases  CD127+ILCs  in  HIV-­1  infection.  
    
HIV-­1  Reveals  the  Plasticity  of  CD127-­ILC1s  
The  experiments  demonstrating  reduction  of  CD127-­ILC1s  by  HIV-­1  infection  excluded  
NK  cells  by  gating  out  CD94+  cells  (Figures  2C,  2F,  S3B,  S3D,  S3G,  S4I,  and  S4J).  To  
distinguish   CD127-­ILC1s   from   CD94+NK   cells,   the   anti-­CD94   antibody   was   removed  
from  our  panel  of   lineage  marker  antibodies   (hereafter  denoted  as   *Lin).  Under   these  
conditions,   the   percentage   of   *Lin-­TBX21+   cells,   which   included   the   sum   of   CD127-­
ILC1s  and  NK  cells,  was   similar   between  HIV-­1-­   and  HIV-­1+  people   (Figure  S5A).  As  
compared   with   CD127-­ILC1s,   though,   the   percentage   of   CD94+   NK   cells   in   the   *Lin-­
TBX21+   population  was   increased   in   the   blood   of  HIV-­1+   individuals   (Figures   4A   and  
4B).  This  abnormality  was  evident  whether  blood  was  examined   from   individuals  with  
CD4  cells  >500/mm3  or  <500/mm3  or  with  viremia  >104/ml  or  <102/ml  (Figures  S5B  and  
S5C).  
  
Stimulation   of   PBMCs   with   PMA   and   ionomycin,   IL-­15,   or   IL-­12   +   IL-­15,   caused   an  
increase  in  the  ratio  of  CD94+NK  cells  to  CD127-­ILC1s,  similar  that  observed  with  HIV-­1  
infection  (Figures  4C,  4D,    S5D  and  S5E).  In  our  assay,  the  levels  of  Ki67  and  Annexin  
V   were   similar   on   the   CD127-­ILC1s   and   CD94+NK   cells,   suggesting   that   observed  
differences  in  percentages  of  these  cells  in  vivo  do  not  result  from  intrinsic  differences  in  
the  rates  of  proliferation  or  apoptosis  (Figures  S5F-­S5H).  
  
Though   ILC1s   and   NK   cells   are   considered   developmentally   distinct   in   the   mouse  
(Klose   et   al.,   2014;;   Spits   et   al.,   2016),   all   human   ILCs,   including   NK   cells,   can   be  
derived   from  a  common  Lin-­CD117+  progenitor   (Lim  et  al.,  2017).   In  keeping  with   this  
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observation,  our  results  above  suggested  that  human  CD127-­ILC1s  become  NK  cells  in  
response   to   immune   stimulation.   ILC   plasticity   has   been   demonstrated   for  
CRTH2+ILC2s   and  RORγT+ILC3s,   either   of   which  may   become  CD127+TBX21+ILC1s  
(Bernink  et  al.,  2015;;  Lim  et  al.,  2016).  To  test  whether  CD127-­ILC1s  also  exhibit  such  
plasticity,   CD127-­ILC1s  were   sorted   by   flow   cytometry   (Figure   S5I)   and   stimulated   in  
vitro   with   PMA   and   ionomycin,   or   with   IL-­12   and   IL-­15.   In   response   to   stimulation,  
CD127-­ILC1s   became   CD94+NK   cells   (Figures   4E-­4G   and   S5J)   with   increased  
degranulation  activity  (Figures  4H  and  S5K).  In  the  absence  of  exogenous  stimulation,  
CD94+NK   cells   sorted   directly   from   blood   had   greater   killing   activity   than   did  CD127-­
ILC1s  (Figure  4I).  Thus,   like  other  ILC  subsets  (Bernink  et  al.,  2015;;  Lim  et  al.,  2016),  
CD127-­ILC1s  exhibit   plasticity,  with   the  ability   to  become   functional  CD94+NK  cells   in  
response  to  stimulation.  
  
To  better   understand   the  molecular   basis   for  CD127-­ILC1s  becoming  CD94+NK  cells,  
RNA-­Seq  was  performed  with  CD127-­ILC1s  and  NK  cells  sorted   from   two  donors.  As  
compared  with  CD94+NK  cells,  CD127-­ILC1s  expressed  70  genes  at  higher   level  and  
140   genes   at   lower   level   (Figure   4J;;   Table   S2).   Consistent   with   the   observation   that  
CD94+NK   cells   result   from   stimulation   of   CD127-­ILC1s,   CD44,   CD2,   and  CXCR3,   as  
well   as   cytolytic   molecule   GZMK,   were   expressed   at   higher   level   on   CD94+NK   cells  
(Figure   4J).   Proteins   encoded   by   nine   of   the   differentially   expressed   genes   were  
confirmed   to   be   produced   in   a   correspondingly   differential  manner   by   flow   cytometry  
(Figure  4K).  
    
CD127-­ILC1s  are  Precursors  of  TCF7+NK  Cells  
Single-­cell  RNA-­Seq  by  high-­content,  droplet  barcoding  (Klein  et  al.,  2015)  was  used  to  
capture  the  transcriptome  of   individual  cells  across  the  spectrum  from  CD127-­ILC1s  to  
CD94+NK   cells   (Figures   5A,   S6A;;   Table   S3).   CD94   was   used   to   identify   NK   cells  
(Hazenberg  and  Spits,  2014)  but  transcriptional  profiling  indicated  that  this  cell  surface  
protein  was  not  sufficient  to  separate  all  CD94+NK  cells  from  CD127-­ILC1s  (Figure  5A).  
Interestingly,  CD94  mRNA  levels  were  identical  in  CD127-­ILCs  and  NK  cells,  indicating  
that  CD94  protein  synthesis  is  primarily  regulated  post-­transcriptionally  (Figure  S6B).  
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In   contrast,   unbiased   clustering,   ignoring   whether   or   not   a   given   cell   was   CD94+,  
showed  two  distinct  cell  populations  (Figure  5B).  The  validity  of  clustering  cells  into  two  
groups  was  confirmed  by  calculating  prediction  strength  as  a  function  of  cluster  number  
(Tibshirani   and   Walther,   2005)   (Figure   S6C).   Cluster   1   was   homogeneous   and  
consisted   of   396   CD94+NK   cells   (Figure   5B,   lower   left).   Cluster   2   contained   371  
CD94+NK  cells  and  973  CD127-­ILC1s  (Figure  5B,  upper  right).  A  heatmap  was  created  
based  on  the  transcriptome  of  3,277  single  cells  collected  from  two  donors,  utilizing  all  
differentially  expressed  genes  from  the  spectral  cluster  analysis  (Figure  5C;;  Table  S4).  
This   showed   a   clear   shift   in   the   pattern   of   gene   expression   along   the   continuum   of  
CD94  expression  (see  blue  and  yellow  bars  at  the  top  of  Figure  5C)  .  
  
To   determine   whether   the   observed   heterogeneity   in   the   individual   CD127-­ILC1  
transcriptomes  was  a  reflection  of  cells  caught  at  different  stages  in  the  CD127-­ILC1  to  
NK  cell  transition,  a  minimum  spanning  tree  was  constructed  using  Monocle  (Trapnell  et  
al.,   2014)   based   upon   the   transcriptome   of   individual   cells   (Figure   5D).   When   the  
heatmap  was   reconstructed  utilizing   the  pseudotime  ordering  of   single  cells  based  on  
the  minimum  spanning  tree  (Figure  S6D),  the  pattern  was  nearly  indistinguishable  from  
the   heatmap   ordered   by   hierarchical   clustering   (Figure   5C),   confirming   the   validity   of  
arranging   cells   along   the   transcriptional   timeline   that   had   been   assigned   by   the  
minimum  spanning  tree.  
  
Differential  expression  analysis  based  on  the  pseudotemporal  ordering  of  cells  from  the  
minimum   spanning   tree   was   used   to   identify   genes   that   regulate   the   transition   from  
CD127-­ILC1s   to   CD94+   NK   cells.   TCF7,   a   gene   that   encodes   a   WNT   pathway  
transcription  factor  (Nusse  and  Clevers,  2017)  critical  for  memory  CD8+  memory  T  cells  
(Utzschneider   et   al.,   2016),   was   only   expressed   in   the   homogeneous  NK   cell   cluster  
(Figure  5E,  5F;;  p  <  7  x  10-­103).  Similar  differential  expression  patterns  were  observed  for  
CD44,  a  gene  important  for  T  cell  survival  and  establishment  of  memory  cells  (Baaten  et  
al.,   2010)   (Figure   5F),   for   PIM3,   a   serine-­threonine   kinase   that   blocks   apoptosis   and  
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promotes   self-­renewal   (Aksoy   et   al.,   2007),   and   for   CD62L,   GZMK,   and   CXCR3  
(Figures  5F).  
  
TCF7+NK   cells   examined   by   flow   cytometry   were   exclusively   CD56hi   (Figure   S6E),   a  
marker  for  NK  cells  with  capacity  to  proliferate  and  differentiate  into  CD56dim  effector  NK  
cells   (Moretta,   2010).   CXCR6,   a   gene   required   for   memory   NK   cell   generation   in  
response   to   haptens   and   viruses   (Paust   et   al.,   2010)   was   also   highly   enriched   on  
TCF7+NK  cells,  as  were  CD44,  CD62L  and  CXCR3  (Figure  S6E).  
  
The  effect   of   cytokine   stimulation   on   the  NK   cell  markers   identified   by  RNA-­Seq  was  
examined   next.   When   sorted   CD127-­ILC1s   were   stimulated   with   IL-­12   and   IL-­15   to  
become  CD94+,   the  cells  also  became  TCF7+   (Figures  S7A  and  5G)  and  upregulated  
CD44,   CXCR3,   CXCR6,   and  GZMK   (Figure   5G).     When   sorted   TCF7+NK   cells   were  
stimulated   with   cytokines,   TCF7   was   downregulated   on   those   cells   that   proliferated  
(Figure   S7A   and   S7B),   analogous   to   CD8+   memory   T   cells   that   downregulate   TCF7  
when   stimulated   to   divide   (Lin   et   al.,   2016a).   TCF7,   then,   defines   an  NK   subset   that  
bears  cell  surface  markers  of  memory  NK  cells  and  T  cells.  
    
WNT   Inhibition   Blocks   the   Cytokine   Induced   Transition   of   CD127-­ILC1   into   NK  
Memory  Cells  
To  determine  if  TCF7  drives  the  cytokine-­stimulated  transition  of  CD127-­ILC1s  into  NK  
cells,  PBMCs  or  sorted  CD127-­ILC1s  were  treated  with  LGK974,  a  potent  but  non-­toxic  
inhibitor  of  WNT  signaling  (Liu  et  al.,  2013)  that  is  currently  being  tested  in  clinical  trials  
(https://clinicaltrials.gov/ct2/show/NCT01351103).   LGK974   blocked   the   cytokine-­
induced  transition  of  CD127-­ILC1s  to  NK  cells,  as  evidenced  by  blockade  of  induction  of  
the   NK   cell   specific   markers   CD94,   CD44,   CXCR3   and   CD56hi   (Poli   et   al.,   2009)  
(Figures   6A-­6F   and   S7C-­S7E).   The   effect   of   LGK974   was   specific   in   that   the   drug  
caused  no  signs  of  toxicity  when  cells  were  examined  following  culture  in  the  drug  for  16  
hrs  or  eight  days,  with  or  without  stimulation  (Figure  S7F);;  in  the  absence  of  stimulation,  
LGK974   alone   caused   no   change   in   the   CD94-­/CD94+   ratio   within   the   *Lin-­TBX21+  
population  (Figure  S7F);;  in  the  presence  of  stimulation,  total  CD56  was  not  changed  by  
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LGK974  (Figure  S7F);;  and  M-­110,  an  inhibitor  of  the  NK  cell  kinase  PIM3  (Figures  5C  
and  5F),  had  no  effect  on  the  cytokine-­induced  transition  from  CD127-­ILC1s  to  NK  cells  
(Figure   S7G).   These   experiments   provide   evidence   that   TCF7   is   required   for   the  
cytokine-­induced  transition  of  CD127-­ILC1s  to  NK  cells.  
  
The  capacity  of  CD127-­ILC1s  to  generate   functional  NK  memory  cells,  and  the  role  of  
TCF7  in  this  process,  was  assessed  using  an  established  protocol  (Cooper  et  al.,  2009;;  
Romee  et  al.,  2012),  that  is  shown  schematically  in  Figure  S7H.  ILCs  received  a  primary  
stimulus  of  IL-­12,  IL-­15,  and  IL-­18  for  16  hrs  and  then  cells  were  rested  in  IL-­15  alone.  
After   five   days,   cells   were   re-­stimulated   with   IL-­12   and   IL-­15   and   heightened   IFN-­γ  
production  was  considered  a  readout  for  an  anamnestic  response  (Figure  S7I).  LGK974  
strongly   inhibited   the   IFN-­γ  memory   response   in  all   13  donors   tested   (Figure  6G  and  
6H)   demonstrating   that   TCF7   is   required   for   the   cytokine-­induced   NK   cell   memory  
response,  attributable  to  CD127-­ILC1  plasticity.  
    
Expansion  of  TCF7+  Memory  NK  Cells  in  HIV-­1  Infection  
In  blood  from  HIV-­1  negative  people,  TCF7  was  detected   in  CD94+NK  cells  but  not   in  
CD127-­ILC1s  (Figures  4K,  5E,  5F,  S6E,  7A  and  7B).   In  contrast,   in  blood  from  HIV-­1+  
people,  the  TCF7+CD94+NK  cell  population  was  greatly  increased  and  TCF7  was  even  
detectable   among   CD127-­ILC1s   (Figures   7A   and   7B),   indicating   that   HIV-­1-­induced  
immune   activation   increased   the   memory   NK   cell   population.   This   newly   described  
plasticity  of  CD127-­ILC1s,  driven  by  TCF7,  offers  explanation  for  the  increased  NK  cell  
memory   reported   with   HIV-­1   infection   (Cerwenka   and   Lanier,   2016;;   Reeves   et   al.,  
2015).  Additionally,  NKG2C,  a    C-­type  lectin  protein  that  is  upregulated  on  memory  NK  
cells  specific  for  human  cytomegalovirus  (Lee  et  al.,  2015)  was  also  elevated  by  HIV-­1  
infection  (Figure  7C  and  7D).  Thus,  CD127-­ILC1  plasticity  driven  by  TCF7  may  serve  as  
a  common  mechanism  for  memory  NK  cell  formation  in  different  contexts.  Analogous  to  
the  effector  memory  T  cells   that  are   increased  with  HIV-­1   infection  (Massanella  et  al.,  
2015),   TCF7+   memory   NK   cells   and   effector   NK   cells   both   likely   derive   from   the  
response  of  CD127-­ILC1s  to  immune  stimulation  (Figure  7E).  
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DISCUSSION  
Studies  on  human  tissues  have  largely  used  cell  surface  CD127  as  necessary  criterion  
for  defining  cells  as  ILCs  (Björklund  et  al.,  2016;;  Hazenberg  and  Spits,  2014;;  Kløverpris  
et  al.,  2016;;  Spits  et  al.,  2013).  The  experiments  reported  here  show  that  this  practice  
has   consequences   for   understanding   ILC   biology   in   the   context   of   human   pathology.  
The  vast  majority   of   ILC1s  and   ILC3s   in   the  blood,  as  well   as  most   ILC1s  and  many  
ILC3s  in  the  colon  lamina  propria,  are,  surprisingly,  CD127-­  (Figures  1B-­1D,  1F,  1I  and  
1J).  Additionally,  these  cells  constituted  the  majority  of  cord  blood  ILCs  (Figures  1E,  1G  
and  1H).  CD127-­ILCs  differed  from  their  CD127+  counterparts  with  respect  to  a  number  
of   cell   surface  markers   (Figure  S2D).  Given   the   relatively   high   percentage  of  CD127-­
ILCs,   these   cells   clearly   should   not   be   excluded   from  analysis.  More   importantly,   the  
assessment  of   these  populations  within   the  context  of  HIV-­1   infection   that   is   reported  
here   offered   insight   into   the   mechanisms   underlying   inflammatory   pathology   and  
revealed  plasticity  of  ILC  subsets  that  was  not  otherwise  evident.  
The  non-­AIDS,   inflammatory  pathology  associated  with  HIV-­1   infection   is  attributed,  at  
least   in  part,   to  chronic  disruption  of   the   intestinal  epithelium   (Brenchley  et  al.,  2006).  
The  integrity  of  the  epithelium  is  maintained  by  homeostatic  cytokines  such  as  IL-­22  that  
are  produced  by   ILC3s  (Cella  et  al.,  2009;;  Zheng  et  al.,  2008).  The  experiments  here  
demonstrate   ILC   abnormalities   within   the   colon   lamina   propria   of   people   who   are   on  
effective   antiviral   treatment   for   chronic  HIV-­1   infection.  Given   that   blood  CD127+ILCs  
are   disrupted   soon   after   HIV-­1   infection   (Kløverpris   et   al.,   2016)   it   is   likely   that   the  
abnormalities   in   the   colon   lamina   propria   CD127+ILCs   detected   here   are   also  
established   early,   during   acute   HIV-­1   infection.   The   specific   abnormalities   that   were  
detected  here  provide  insight  into  the  etiology  and  mechanism  underlying  this  persistent  
pathology.  CD127+ILC3s,  but  not  CD127-­ILC3s,  were  depleted  from  the  colon  (Figures  
2K   and  S3J).   IL-­22   production  was   readily   detected   among  CD127+ILC3s,   but   not   in  
CD127-­ILC3s.   These   observations,   diagramed   schematically   in   Figure   2L,   offer  
explanation  for  ongoing  inflammation  with  chronic  HIV-­1  infection.  
CD127+ILCs  appear  not  to  be  eliminated  as  a  result  of  direct  infection  by  HIV-­1.  These  
cells   lack  HIV-­1  entry   receptors  and  challenge  with  HIV-­1  yielded  negative   results   for  
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productive   infection,   in   our   hands   and   those   of   others   (Kløverpris   et   al.,   2016).   The  
cause   for   the   specific   disruption   of   CD127+ILCs   in   response   to   HIV-­1   infection   was  
sought  here   from  among  26   factors   -­   cytokines,  chemokines,  and  bacterial  products   -­  
that  have  been  reported  to  be  elevated  systemically  with  HIV-­1  infection  (Brenchley  et  
al.,   2006;;   Deeks   et   al.,   2013;;   Favre   et   al.,   2010;;   Kacani   et   al.,   1997;;   Roberts   et   al.,  
2010;;  Shebl  et  al.,  2012;;  Stacey  et  al.,  2009;;  Swaminathan  et  al.,  2016).   It  was  found  
that   IL-­2,   IL-­4,   IL-­7,   and   IL-­15,   all   cytokines   that   signal   through   the   common   gamma  
chain  receptor  in  a  JAK3-­dependent  fashion  (Leonard  and  O’Shea,  1998;;  Suzuki  et  al.,  
2000)  downregulated  CD127  on  ILCs  (Figures  3C  and  3E).  These  findings,  along  with  
the   persistence   of   CD127-­ILC3s   in   the   blood   and   colon   of   HIV-­1+   people   whose  
CD127+ILCs  were  decreased,  indicate  that,  rather  than  simply  being  eliminated  by  HIV-­
1   infection,   ILCs   downregulate   CD127,   and   the   phenotype   of   these   cells   changes   in  
response  to  inflammatory  cytokines.  Though  IL-­7  and  its  cognate  receptor,  CD127,  are  
considered  essential   for   ILC  development   (Spits  and  Di  Santo,  2011;;  Vonarbourg  and  
Diefenbach,   2012),   CD127   is   apparently   not   required   for   maintenance   of   all   ILC  
subtypes.   The   number   of   lymphoid-­tissue-­inducer   (LTi)   cells,   a   subset   of   ILC3s,   was  
normal   in   blood   and   spleen   of   newborn   CD127-­/-­   or   IL-­7-­/-­   mice   (Luther   et   al.,   2003;;  
Schmutz  et  al.,  2009).  Better  understanding  of   the  plasticity  of   the   lamina  propria   ILC  
populations,   and   loss   of   their   homeostatic   function   in   response   to   inflammation,  may  
lead  to  new  therapies  that  limit  the  inflammatory  sequelae  of  HIV-­1  infection  and  other  
diseases.  
HIV-­1  infection  was  associated  with  reduction  in  the  percentage  of  blood  CD127-­ILC1s  
(Figures   2C   and   2F)   and   this  was   accompanied   by   an   increase   in   the   percentage   of  
CD94+NK   cells   (Figures   4A   and   4B).   In   vitro   stimulation   of  CD127-­ILC1s   from  HIV-­1-­  
blood   converted   these   cells   into   CD94+NK   cells   with   increased   degranulation   activity  
and   cytotoxicity   (Figures   4E-­4I),   in   agreement   with   the   increased   cytotoxic   activity  
others  have   reported   for  CD94+NK  cells   (Davis  et  al.,  2016;;  Yu  et  al.,  2009),  and   the  
finding   that   all   human   ILCs,   including   NK   cells,   can   be   derived   from   a   common   Lin-­
CD117+   progenitor   (Lim   et   al.,   2017),   The   CD94+NK   cells,   which   included   CD56hiNK  
cells,   bore   higher   levels   of   activation  markers   than   did  CD127-­ILC1s   (Figures   4J   and  
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4K).  The  data  indicate  that,  rather  than  being  killed  off  by  HIV-­1  infection,  CD127-­ILC1s  
are  converted  into  CD94+NK  cells  by  HIV-­1  associated  inflammation.  
Clustering   of   transcriptomes   from   thousands   of   individual   cells   from   HIV-­1-­   blood  
revealed   a   pseudotime   developmental   trajectory   (Trapnell   et   al.,   2014)   from   CD127-­
ILC1s   to  CD94+NK   cells   that   tracked  with   expression   of   the  WNT   transcription   factor  
TCF7   (Figure   5D).  Reverse   genetic   experiments   attempting   to   perturb   the   function   of  
TCF7  were  attempted  but  the  titer  of   lentiviral  or  AAV  vectors  on  human  CD127-­ILC1s  
was   too   low   to  generate  statistically   significant  phenotypes.   Instead,  LGK974,  a  WNT  
inhibitor   of   clinical   utility  was  exploited   to   show   that   this   signaling   pathway  drives   the  
CD127-­ILC1   to  NK  cell   transition  and   the  establishment  of  NK  cell  memory  (Figures  5  
and  6).  
The  TCF7+NK  cells  that  were  enriched  with  HIV-­1  infection  had  markers  that  have  been  
reported  for  memory  NK  cells,  including  CD44,  CXCR6,  NKG2C  and  CD94.  (Figure  7C,  
7D  and  S6E).  One  of  the  hallmarks  of  memory  lymphoid  cells  is  the  ability  to  proliferate  
quickly   with   enhanced   effector   function   upon   restimulation.   The   TCF7+   cells   were  
CD56hi   (Figure   S6E),   a   population   of   NK   cells   that   exhibits   the   highest   proliferation  
ability   among  NK   subsets   (Caligiuri   2008).   TCF7   regulates  CD44   expression   (van   de  
Wetering  et  al.,  2002)  and  the  developmental  trajectory  in  Figures  5D  and  5E  indicates  
that   TCF7   is   critical   for   establishment   of   these  memory-­associated   NK  markers.   The  
increase  in  CD94+NK  cells  (Figures  4A  and  4B)  and  in  TCF7+NK  cells  (Figures  7A  and  
7B)   that   was   observed   with   HIV-­1   infection   may   very   well   account   for   the   reported  
increase   in  NK   cell  memory   responses  with   this   infection   (Deeks,   2011;;   Paust   et   al.,  
2010).   TCF7/WNT   signaling   inhibitor   LGK974,   which   inhibited   immune   stimulation  
induced  transition  of  CD127-­ILC1  to  NK  cells  and  the  establishment  of  memory  NK  cells  
with   increased   IFN-­γ   response   to   secondary   stimulation,  might   offer   clinical   benefit   in  
treating  HIV-­1  related  chronic  inflammation.  Taken  together,  these  experiments  indicate  
that   the   shift   from   CD127-­ILC1s   to   CD94+NK   cells   that   was   observed   with   HIV-­1  
infection  reflects  ILC  plasticity  that  is  part  of  normal  NK  cell  physiology.  
  
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/221010doi: bioRxiv preprint first posted online Nov. 17, 2017; 
17  
MATERIALS  AND  METHODS  
    
Clinical  samples.  All  human  blood  and  colon  samples  were  collected  from  participants  
who  had  provided  written  informed  consent  for  protocols  that  included  study  of  cellular  
immunity  in  HIV-­1  infection,  in  accordance  with  procedures  approved  by  the  University  
of   Massachusetts   Medical   School   (UMMS)   Institutional   Review   Board.   Routine  
screening  colonoscopy  was  scheduled  as  medically  indicated.  HIV-­1-­  control  individuals  
undergoing   colonoscopy   the   same   day   were   matched   for   gender   and   age.   In   pilot  
experiments  with  two  patients,  multiple  biopsies  of  different  segments  of  the  bowel  from  
the   same   patient   were   compared   and   no   differences   in   ILC   populations   were   found.  
Subsequent  sampling  was  from  the  descending  colon  only.  All  patients  were  consented  
the   day   of   the   procedure.   All   blood   and   colon   samples   that   were   collected   and  
processed   were   included   in   the   data   analysis   after   simple   allocation   into   one   of   two  
groups,  HIV-­1-­  or  HIV-­1+.  Attempts  to  stratify  samples  according  to  viral  load  or  CD4+  T  
cell   count   of   the   donor   failed   to   detect   significant   differences   between   the   subgroups  
(Figures  S3  and  S5).  
    
Antibodies  and  reagents.  The  antibodies  and  reagents  used  in  this  study  was  included  
in  Table  S5  and  Table  S6.  
    
Human  mononuclear  cell   isolation.  Human  peripheral  blood  or  umbilical  cord  blood  
was   diluted   with   an   equal   volume   of   RPMI-­1640   (Gibco),   overlaid   on   Histopaque  
(Sigma),  and  centrifuged  at  500  x  g  for  30  mins  at  room  temperature.  Mononuclear  cells  
were  washed  3  times  with  MACS  buffer  (0.5%  BSA  and  2  mM  EDTA  in  PBS)  and  either  
used  immediately  or  frozen  in  FBS  containing  10%  DMSO.  
    
Human  intestinal  lamina  propria  lymphoid  cell  (LPL)  preparation.  Human  intestinal  
biopsies  were  incubated  with  PBS  containing  5  mM  EDTA,  150  μg/ml  DTT,  and  0.1%  β-­
mercaptoethanol   on   a   shaker   for   15   min   at   37℃   to   remove   epithelial   cells.   The  
remaining  tissue  containing  the  LPLs  was  washed  with  complete  RPMI-­1640  (10%  FBS,  
1:100   GlutaMAX,   and   1:1000   β-­mercaptoethanol),   then   digested   with   RPMI-­1640  
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containing  125  μg/ml  Liberase  (Roche)  and  200  μg/ml  DNase  I  (Sigma)  for  30  min  on  a  
shaker  at  37℃.  LPLs  were  filtered  through  a  70  μm  cell  strainer  and  washed  with  RPMI-­
1640.  
    
Definition  of  human  lineage-­negative  lymphoid  populations.  Live  singlets  of    human  
PBMCs,   or   of   intestinal   lamina   propria   lymphoid   cells,   were   stained   with   a   panel   of  
lineage   markers   (Lin):   anti-­CD3,   anti-­TCRαβ,   anti-­CD19,   anti-­B220,   anti-­CD34,   anti-­
FcεRIα,   anti-­CD11c,   anti-­CD303,   anti-­CD123,   anti-­CD1a,   anti-­CD14,   and   anti-­CD94.  
The   specific   antibodies   used   are   listed   in   Table   S5.   Cells   that   were   negative   for   all  
lineage  markers  were  defined  as  lineage-­negative  (Lin-­)  lymphoid  cells.  As  indicated  in  
some  experiments,  the  anti-­CD94  antibody  was  not  included  in  the  antibody  panel;;  cells  
that  were  negative  after  staining  with  these  antibodies  were  designated  *Lin-­.  
    
Human   CD127-­ILC1   and   NK   cell   enrichment.   CD127-­ILC1s   and   NK   cells   were  
negatively  enriched  by  excluding  T  cells,  B  cells,  stem  cells,  dendritic  cells,  monocytes,  
granulocytes,  and  erythroid  cells  with  the  human  NK  isolation  kit   (MACS)  according  to  
manufacturer's  instruction.  
    
Flow  cytometry.  Live  and  dead  cells  were  discriminated  using  the  Live  and  Dead  violet  
viability   kit   (Invitrogen,   L-­34963).   For   cell   surface   molecule   detection,   the   cells   were  
resuspended   in  antibody-­containing  MACS  buffer   for  30-­60  min  at  4°C   in   the  dark.  To  
detect  cytokine  production,  cells  were  stimulated  with  the  indicated  cytokines  for  16  hrs,  
or  with  PMA  and   ionomycin   (cell   stimulation  cocktail  00-­4970-­03,  ebioscience)   for  3-­6  
hrs.   In   both   cases,   protein   transport   inhibitor   (00-­4980-­03,   eBioscience)   was   present  
during  the  stimulation.  For  intracellular  staining  of  transcription  factors  or  cytokines,  cells  
were   fixed  and  permeabilized  using  Foxp3  staining  buffer  kit   (eBioscience)  and   target  
intracellular  molecules  were  stained  as  for  surface  staining.  
    
Cell  sorting.  PBMCs  were  stained  with  a  panel  of   lineage  markers   that   included  anti-­
CD3,   anti-­TCRαβ,   anti-­CD19,   anti-­B220,   anti-­CD34,   anti-­FcεRIα,   anti-­CD11c,   anti-­
CD303,   anti-­CD123,   anti-­CD1a,   and   anti-­CD14.   The   lineage   negative   population  was  
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designated  *Lin-­  to  distinguish  it  from  the  full  Lin-­  population  which  additionally  included  
the  anti-­CD94  antibody.  For   sorting,   *Lin-­   cells  were   then   stained  with   anti-­CD56  and  
anti-­CD94   antibodies.   CD127-­ILC1s   (*Lin-­CD56+CD94-­),   total   NK   cells   (*Lin-­
CD56+CD94+)   and   TCF7+NK   cells   (*Lin-­CD56hiCD94+)   were   sorted   using   a   BD  
FACSAria  IIu.  
    
Degranulation  assay.  PBMCs  were  seeded   in  a  24  well  plate  at  2  ×  106  cells/well   in  
RPMI-­1640  with  anti-­CD107a  antibody  (Biolegend,  1:200).  Then,  cells  were  treated  with  
PMA/ionomycin   and   protein   transport   inhibitor   for   5   hrs   in   a   37℃   incubator   with   5%  
CO2.  Surface  CD107a  was  detected  by  flow  cytometry.  
    
Killing   assay.  K562   or   Jurkat   cells   were   washed   and   resuspended   at   106   cell/ml   in  
PBS.  Calcein-­AM  (Neri  et  al.,  2001)   (Molecular  Probes)  was  added  at  10  μM  and   the  
cells  were  labelled  at  37°C  in  5%  CO2  for  30  min.  After  washing  with  PBS  for  2  times,  
the   labelled   cells   were   resuspended   in   complete   RPMI-­1640   and   aliquoted   in   a   V  
bottom   96   well   plate   (5,000   cells   in   100   μl).   The   sorted   ILC1   or   NK   cells   were  
resuspended  in  complete  RPMI-­1640  and  the  concentration  was  adjusted  at  15  fold  of  
target   cells   (7.5×104   cells)   in   50μl.   The   effector   and   target   cells   were   mixed   and  
centrifuged  at  50  x  g  for  0.5  min  and  were  incubated  at  37°C  in  5%  CO2  for  6  hrs.  Cells  
were   pelleted   and   100   μl   supernatant   was   transferred   to   a   96-­well   solid   black  
microplate.   The   fluorescence      released   by   labelled   target   cells   were   detected   using  
BioTek   Synergy   2   plate   reader   (excitation   filter:   485/20   nm;;   band-­pass   filter:   528/20  
nm).   Specific   lysis   was   determined   as:   [(test   fluorescence   release   -­   spontaneous  
fluorescence   release)   /   (maximum   fluorescence   release   -­   spontaneous   fluorescence  
release)]  ×  100.  
    
Real-­time   quantitative   PCR   (qRT-­PCR).   The   RNA   of   sorted   CD127-­ILC1s   and   NK  
cells   were   extracted   using   TRIzol   reagent   (invitrogen,   15596018)   according   to  
manufacturer's   instruction.   Reverse   transcription   were   performed   using   SuperScript  
VILO  Master  Mix   (invitrogen,   11755050),   and  CD94  mRNA   level  were   determined   by  
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qRT-­PCR,  using   taqman  probe  (Applied  Biosystems,  Hs00233844_m1),  GAPDH  were  
detected  as  an  internal  control  (Applied  Biosystems,  Hs03929097_g1).  
    
Library   preparation   for   bulk   RNA-­Seq.   The   bulk   RNA   sequencing   library   was  
prepared   using   CEL-­Seq2   (Hashimshony   et   al.,   2016).   RNA   of   sorted   cells   was  
extracted  using  TRIzol   reagent.   10  ng  RNA  was  used   for   first   strand  cDNA  synthesis  
using   barcoded   primers   containing   unique   molecular   identifier   (UMI)   sequences.  
Specifically,   the  RNA  of  CD127-­ILC1s  was  reverse  transcribed  with  5’-­GCC  GGT  AAT  
ACG  ACT  CAC  TAT  AGG  GAG  TTC  TAC  AGT  CCG  ACG  ATC  NNN  NNN  AGA  CTC  
TTT  TTT  TTT  TTT  TTT  TTT  TTT  TTT  V-­3’  and  5’-­GCC  GGT  AAT  ACG  ACT  CAC  TAT  
AGG  GAG  TTC  TAC  AGT  CCG  ACG  ATC  NNN  NNN  CAG  ATC  TTT  TTT  TTT  TTT  TTT  
TTT  TTT  TTT  V-­3’.  The  RNA  of  CD94+NK  cells  was   reverse   transcribed  with  5’-­GCC  
GGT  AAT  ACG  ACT  CAC  TAT  AGG  GAG  TTC  TAC  AGT  CCG  ACG  ATC  NNN  NNN  
CAT  GAG  TTT  TTT  TTT  TTT  TTT  TTT  TTT  TTT  V-­3’  and  5’-­GCC  GGT  AAT  ACG  ACT  
CAC  TAT  AGG  GAG  TTC  TAC  AGT  CCG  ACG  ATC  NNN  NNN  TCA  CAG  TTT  TTT  
TTT  TTT  TTT  TTT  TTT  TTT  V-­3’.    The  second  strand  was  synthesized  using  NEBNext  
Second  Strand  Synthesis  Module  (NEB).  The  pooled  dsDNA  was  purified  with  AMPure  
XP  beads  (Beckman  Coulter,  A63880)  and  subjected  to  in  vitro  transcription  (IVT)  using  
HiScribe   T7   High   Yield   RNA   Synthesis   Kit   (NEB),   then   treated   with   ExoSAP-­IT  
(Affymetrix   78200).   IVT   RNA   was   fragmented   using   RNA   fragmentation   reagents  
(Ambion)  and  underwent  a  2nd  reverse  transcription  step  using  randomhexRT  primer-­5’-­
GCC  TTG  GCA  CCC  GAG  AAT  TCC  ANN  NNN  N-­3’  to  incorporate  the  second  adapter.  
The  final  library  was  amplified  with  indexed  primers:  RP1-­5’-­AAT  GAT  ACG  GCG  ACC  
ACC  GAG  ATC  TAC  ACG  TTC  AGA  GTT  CTA  CAG  TCC  GA-­3’  and  RPI1-­5’-­CAA  GCA  
GAA  GAC  GGC  ATA  CGA  GAT  CGT  GAT  GTG  ACT  GGA  GTT  CCT  TGG  CAC  CCG  
AGA  ATT  CCA-­3’  and  the  purified  library  was  quantified  with  4200  TapeStation  (Agilent  
Technologies)   and   paired-­end   sequenced   on   a   Nextseq   500   V2   (Illumina)   using   15  
cycles  Read  1,  6  cycles  Index  1,  and  71  cycles  Read  2.  
    
Library  preparation  for  single  cell  RNA-­Seq.  The  single  cell  sequencing   library  was  
prepared  using   InDrop  barcoding   (Klein  et  al.,  2015).   Individual,  pre-­sorted  cells  were  
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captured  in  droplets  containing  lysis  buffer,  reverse  transcription  reagents,  and  hydrogel  
microspheres   carrying   primers   for   barcoding,   each   captured   cell   using   a   custom-­built  
InDrop  microfluidics  system,  as  described  (Klein  et  al.,  2015).  After  cDNA  for  each  cell  
was  synthesized  in   individual  droplets  with  unique  barcodes,  the  droplet  emulsion  was  
broken  and  cDNA   from  all   cells  was  pooled.  A  single  cell   cDNA   library  was  prepared  
using   essentially   CEL-­Seq2   (Hashimshony   et   al.,   2016)   as   described   above   for   bulk  
RNA-­Seq,  with  the  following  changes.  PE2-­N6-­5’-­TCG  GCA  TTC  CTG  CTG  AAC  CGC  
TCT   TCC   GAT   CTN   NNN   NN-­3’   was   used   in   the   2nd   reverse   transcription   reaction.  
CD127-­ILC1  libraries  were  linearly  amplified  with  Indexed  primers  PE1-­6:  5’-­CAA  GCA  
GAA  GAC  GGC  ATA  CGA  GAT  ATT  GGC  CTC  TTT  CCC  TAC  ACG  A-­3’  or  PE1-­17:  5’-­
CAA  GCA  GAA  GAC  GGC  ATA  CGA  GAT  CTC  TAC  CTC  TTT  CCC  TAC  ACG  A-­3’  
and  PE2:  5’-­AAT  GAT  ACG  GCG  ACC  ACC  GAG  ATC  TAC  ACG  GTC  TCG  GCA  TTC  
CTG  CTG  AAC-­3’.     Libraries   from  CD94+NK  cells  were  amplified  with   index  1  primers  
PE1-­12:  5’-­CAA  GCA  GAA  GAC  GGC  ATA  CGA  GAT  TAC  AAG  CTC  TTT  CCC  TAC  
ACG  A-­3’   or   PE1-­18:   5’-­CAA  GCA  GAA  GAC  GGC  ATA  CGA  GAT  GCG  GAC  CTC  
TTT  CCC  TAC  ACG  A-­3’,  and  PE2  (above).  Libraries  were  sequenced  38  cycles  Read  
1,   6   cycles   Index   1,   48   cycles   Read   2   using   Illumina   Nextseq   500   V2   with   custom  
sequencing  primers  added  to  the  cartridge:  R1  5’-­GGC  ATT  CCT  GCT  GAA  CCG  CTC  
TTC  CGA  TCT-­3’  Idx:  5’-­AGA  TCG  GAA  GAG  CGT  CGT  GTA  GGG  AAA  GAG-­3’  R2  5’-­  
CTC  TTT  CCC  TAC  ACG  ACG  CTC  TTC  CGA  TCT-­3’.  
    
Bulk   RNA-­Seq   Processing   and   Analysis.   The   four   pooled   sets   of   RNA-­Seq   reads  
were  separated  by  CEL-­Seq  barcodes  and  mapped  to  the  HG19  genome  using  Tophat  
(Kim  et  al.,  2013)  (version  2.0.14,  default  parameters).  Aligned  reads  were  quantified  by  
ESAT  (Derr  et  al.,  2016)  using  a  transcript  annotation  file  containing  all  RefSeq  genes  
filtered   to  select  only   ‘NM’   transcripts  and  extending   the   transcripts  up   to  1,000  bases  
past   the   end   of   the   annotated   3’   end   (-­wExt   1000,   -­task   score3p),   discarding  
multimapped  reads  (-­multimap   ignore).  Differential  expression  analysis  was  performed  
using   DESeq2   (Love   et   al.,   2014),   contrasting   the   CD127-­ILC1   samples   with   the  
CD94+NK   cell   samples.  Differentially   expressed   genes  were   selected   if   the   log2   fold-­
change  was  greater  than  1.0,  with  p  <0.05.  
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Single   cell   RNA-­Seq   processing   and   analysis.   Reads   were   mapped   to   the   HG19  
genome  using  Tophat  (Kim  et  al.,  2013)  (version  2.0.14,  default  parameters).  To  assign  
each   read   to   a   given   cell   and   collapse   duplicate   reads   into   single   UMIs,   alignments  
were   processed   by   ESAT   (Derr   et   al.,   2016)   using   its   single-­cell   analysis   module   (-­
scPrep)   with   the   same   transcript   annotation   file   used   for   the   bulk  RNA-­Seq   analysis,  
extending   the   transcripts  up   to  1,000  bases  past   the  annotated  3’  end   (-­wExt  1000,   -­
task  score3p),  discarding  multimapped  reads  (-­multimap  ignore),  and  requiring  a  single  
observation  of  a  UMI  for  a  transcript  to  be  counted  (-­umiMin  1).  
The  final  output  of  ESAT  is  a  table  where  rows  are  genes,  cells  are  columns,  and  values  
represent  the  number  of  UMIs  detected  in  each  cell.  The  dataset  was  loaded  into  R  and  
the  packages  used  (if  not  part  of  base  R)  are  noted.  First,  data  was  normalized  using  
the  TMM  method  from  EdgeR  (Robinson  and  Oshlack,  2010).  On  this  matrix,  PCA  was  
run  in  order  to  determine  the  number  of  dimensions  that  contribute  variance  to  the  data  
and   to   select   genes   that   were   highly   variable   in   the   dataset.   ICA   was   run   using   the  
fastICA   (Hyvärinen   and   Oja,   2000)   algorithm   to   reduce   the   data   to   the   number   of  
dimensions  that  contained  variance.  To  determine  the  optimum  number  of  cell  clusters  
in  the  dataset  the  methods  of  (Tibshirani  and  Walther,  2005)  were  utilized.  This  analysis  
showed  2  clusters  gives  the  highest  predictive  strength,  and  that  further  subdividing  of  
the   cells   into   additional   clusters   severely   lowered   the   score.   Spectral   clustering   was  
then  run  with  n  of  2  centers  and  the  symmetrical  method  on  the  cell’s  ICA  components  
using  the  kknn  package  (Hechenbichler  and  Schliep,  2004).  For  visualization,  the  cells  
were   then   reduced   to   2   dimensions   using   the   Rtsne   package,   which   took   the   ICA  
components   as   input   (Van   Der   Maaten,   2014).   Lastly,   the   minimum   spanning   tree  
(MST)  was  constructed  on   the   tSNE  plot  utilizing  Monocle   (Trapnell  et  al.,   2014).  For  
pseudotime   analysis,  Monocle’s   built-­in   differential   expression   tools  were   utilized.   For  
visualization  purposes,  tSNE  mapped  cells  were  color  coded  by  the  expression  of  given  
genes;;  a  weighted  density  map  was  created  that  takes  into  account  both  the  number  of  
cells  in  a  region  as  well  as  their  expression  values.  
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Cytokine  induced  ILC1  and  NK  cell  memory  assay.  PBMCs  or  enriched  CD127-­ILC1  
and  NK   cells  were   pre-­stimulated  with   IL-­15   (5   ng/ml)   +   IL-­12   (10   ng/ml)   +   IL-­18   (50  
ng/ml)   for   16   hrs,   or   cells   were   incubated  with   IL-­15   alone   (5   ng/ml)   to  maintain   cell  
survival   (no   pre-­stimulation,   control).   Cytokines   were   washed   out   and   the   cells   were  
rested  by   incubation   in  IL-­15  (5  ng/ml)  alone  for  5  days.  Cells  were  then  re-­stimulated  
with   IL-­12   (50  ng/ml)  +   IL-­15   (50  ng/ml)   for  16  hrs.   IFN-­γ  production  was  detected  by  
intracellular   staining   with   anti-­IFN-­γ   antibody   using   a   Foxp3   staining   buffer   kit  
(eBioscience).  As  compared  with  cells  that  had  not  been  pre-­stimulated,  the  increase  in  
IFN-­γ   production   in   pre-­stimulated   cells   was   used   as   a   readout   for   pre-­stimulation  
induced  memory,  as  previously  described  (Poli  et  al.,  2009).  
    
Statistics.   Statistical   analysis   was   performed   with   GraphPad   Prism   software   using  
paired  or  unpaired   two-­tailed  student’s   t-test as indicated in the figure legends. p﹤0.05 
was considered as significant. Variance was estimated by calculating the mean ± s.e.m. 
in each group. Variances among groups of samples were compared using the F-test 
function in GraphPad.  
    
RNA-­Seq  datasets.  Our  RNA-­Seq  datasets,  including  bulk  and  single  cell  RNA-­Seq  for  
the   two   FACS   sorted   cell   populations,   from   two   blood   donors,   has   GEO   accession  
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FIGURE  LEGENDS  
Figure  1.     Major  Populations  of  TBX21+ILC1s  and  RORγT+ILC3s  in  Human  Blood  
and  Colon  are  CD127-­  
(A,   B)   Flow   cytometry   for   CD127   versus   pool   of   12   lineage  markers   after   gating   for  
viable,  singlet,  lymphoid  PBMCs  (A),  and  for  TBX21,  CRTH2,  or  RORγT  among  Lin-­  (B).  
(C,   D)   Percentage   of   TBX21+   (C,   n=16),   or   RORγT+   (D,   n=19),   among   the   indicated  
subpopulations.   (E,   F)   CD127   versus   TBX21+   or   RORγT+   among   Lin-­   umbilical   cord  
blood  (E)  or  colon  lamina  propria  lymphoid  cells  (F).  (G,  H)  Percentage  of  the  indicated  
populations   from   cord   blood   (G,   n=15;;   H,   n=16).      (I,   J)   Percentage   of   the   indicated  
populations  from  colon  (I,  n=5;;  J,  n=6).  (K,  L)  TBX21  versus  IFN-­γ,  GM-­CSF,  or  TNFα  
after  Lin-­PBMCs  were  stimulated  with  PMA  and   ionomycin   (K)  or   IL-­12  and   IL-­15   (L).  
(M)  Lin-­ lamina propria lymphoid cells stimulated with PMA and ionomycin and stained 
for CD127 versus IL-22 or IL-13. Data are representative of ≥ 3 donors. Each dot 
represents 1 donor, mean ± s.e.m.; two-tailed, unpaired t-­test;;   ns,   non-­significant,   ∗p﹤
0.05, ∗∗p﹤0.01, ∗∗∗p﹤0.001;  See  also  Figures  S1-­S2.  
    
Figure  2.  CD127+ILCs  and  CD127-­ILC1s  are  Decreased  in  Blood  and  Colon  of  HIV-­
1+  People  on  Effective  Antiviral  Therapy  
(A)  Flow  cytometry   for  12   lineage  markers  versus  CD127  on  PBMCs   from  HIV-­1-­  and  
HIV-­1+   individuals.   (B)   Percentage   of   CD127+   cells   among   Lin-­PBMCs   from   HIV-­1-­  
(n=23),  and  HIV-­1+   (n=28).   (C-­E)  Lin-­PBMCs   from  HIV-­1-­  or  HIV-­1+  were  analyzed  by  
flow   cytometry   with   CD127   and   either   TBX21   (C),   CRTH2   (D)   or   RORγT   (E).   (F-­H)  
Percentage   of   TBX21+   (F),   HIV-­1-­   (n=14),   HIV-­1+   (n=22);;   CRTH2+   (G),   HIV-­1-­   (n=9),  
HIV-­1+   (n=10);;   or   RORγT+   (H),   HIV-­1-­   (n=14),   HIV-­1+   (n=21),   from   (C-­E).   (I)   Human  
lamina  propria   lymphocytes  were  detected  with   12   lineage  markers   and  CD127   (left),  
and  Lin-­  cells  were  further  analyzed  with  CD127  and  RORγT  (right).  (J,  K)  Percentage  
of  Lin-­CD127+   (J),  HIV-­1-­   (n=6),  HIV-­1+   (n=7),  or  Lin-­RORγT+CD127+   (K),  HIV-­1-­   (n=6),    
HIV-­1+   (n=7).   (L)  Lamina  propria  CD127+ILC3s  maintain   the   integrity  of  gut  epithelium  
by   producing   cytokines   such   as   IL-­22   (left).   HIV-­1   infection   is   associated   with  
irreversible  elimination  of  CD127+ILCs  and  disrupted   intestinal  epithelium  (right).  Each  
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dot   represents   a   unique   sample,   mean   ±   s.e.m.;;   two-­tailed   unpaired   t-­test;;   ns,   non-­
significant,  ∗∗∗p﹤0.001. See also Figure S3.  
    
Figure  3.  HIV-­1  Shifts  the  Balance  from  CD127+ILCs  to  CD127-­ILCs  
(A,  B)  PBMCs  were  stimulated  with  PMA  and  ionomycin,  or  with  the  indicated  cytokines  
for  16  hrs.  The  CD127+ILC  percentage  among  Lin-­TBX21-­  cells  was  determined  by  flow  
cytometry   (A)   and   calculated   (n=3)   (B).   (C)   The   percentage  CD127+ILCs   among   Lin-­  
PBMCs  was  calculated  after  treatment  with  the  indicated  common  γ  chain  cytokines  for  
16  hs  (n=4).   (D)   IL-­7   treatment  shifted  CD127+ILCs  to  CD127-­ILCs;;  CD25  and  CD127  
were  detected  on  Lin-­  PBMC,  with  or  without   IL-­7   treatment.   (E)  PBMCs  were   treated  
with   IL-­7   or   IL-­15   for   16   hrs,   with   or   without   JAK1/2   inhibitor   Ruxolitinib,   or   JAK3  
inhibitor  CP-­690550,  and  the  percentage  CD127+ILCs  among  Lin-­  cells  was  calculated  
(n=4).  mean  ±  s.e.m.,  two-­tailed  unpaired  t-­test,  ∗∗p﹤0.01, ∗∗∗p﹤0.001. See also Figure S4.  
    
Figure  4.  HIV-­1  Shifts  the  Balance  from  CD127-­ILC1s  to  NK  Cells  
(A,  B)  PBMCs   from  HIV-­1-­  and  HIV-­1+  people  were  stained  with   lineage  markers,  but  
leaving   out   the   anti-­CD94   antibody   (*Lin),   and   then   the   percent   CD94-­   and   CD94+  
among  the  *Lin-­TBX21+  population  was  determined  (A),  CD94+/CD94-­   ratio   (B),  HIV-­1-­  
(n=23),   HIV-­1+   (n=26).   (C,   D)   Percent   CD94-­   and   CD94+   among   *Lin-­TBX21+PBMCs  
after  stimulation  with  PMA  and   ionomycin  or   IL-­15   (C),  CD94-­/CD94+   ratio   (D)   (n=10).  
(E-­G)  CD127-­ILC1s  were  sorted  as  *Lin-­CD56+CD94-­,  then  stimulated  with  PMA/iono  (E  
and  F)  or  IL-­12  +  IL-­15  (G)  for  16  hrs,  and  the  percent  CD94+  was  determined  (F,  n=5;;  
G,  n=6).  (H)  PBMCs  were  stimulated  with  PMA/iono  and  the  percentage  CD107a+  cells  
among   CD127-­ILC1s   and   NK   cells   was   calculated   (n=5).   (I)   Percent   specific   lysis   of  
K562   or   Jurkat   cells   by   sorted   CD127-­ILC1s   (*Lin-­CD56+CD94-­)   and   NK   cells   (*Lin-­
CD56+CD94+)   (n=8).   (J)  Heatmap   of   differentially   expressed   genes   by   bulk  RNA-­Seq  
comparing   CD127-­ILC1s   and   CD94+NK   cells,   sorted   from   two   donors.   (K)   Flow  
cytometry  analysis  of  proteins  encoded  by  the  indicated  genes  from  bulk  RNA-­seq  from  
at   least   3   independent   experiments.   Each   dot   represents   a   unique   sample,   mean   ±  
s.e.m.;;   (D,  H,  and  I),   lines  connect  cells   from  common  donor.  (B,  F  and  G),   two-­tailed  
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unpaired  t-­test.  (D,  H,  and  I),  two-­tailed  paired  t-­test;;  ∗p﹤0.05, ∗∗p﹤0.01, ∗∗∗p﹤0.001.  See 
also Figures S4 and S5.  
    
Figure  5.  CD127-­ILC1s  Act  as  Precursors  of  TCF7+NK  Cells  
(A,  B)  Two  dimensional  (tSNE)  plot  of  986  CD127-­ILC1s  and  767  CD94+NK  cells,  color-­
coded  according   to  CD127-­ILC1s  or  CD94+NK  cells   (A),   or   total   cells   segregated   into  
two   clusters   based  on   spectral   clustering   of   single   cell   transcriptomes,  with   k-­nearest  
neighbor,  search=2  (B).  (C)  Heatmap  of  1,729  CD127-­ILC1s  (blue)  and  1,548  NK  cells  
(yellow)   collected   from   2   donors   using   all   differentially   expressed   genes   from   the  
spectral   cluster   analysis.   (D)   Minimum   spanning   tree   based   on   the   transcriptome   of  
individual   cells   showing   the   pseudotime   trajectory   (black   line).   (E)   TCF7   expression  
profile  along  the  pseudotime  trajectory.  (F)  Expression  level  and  density  of  the  indicated  
genes  within  t-­SNE  plots.  (A,  B,  D,  E,  and  F)  data  are  representative  of  two  donors.  (G)  
Sorted   CD127-­ILC1s   (*Lin-­CD56+CD94-­)   were   treated   with   IL-­15   (5   ng/ml)   for   5   days  
then  stimulated  with   IL-­12   (50  ng/ml)  and   IL-­15   (50  ng/ml)   for  16  hrs.  TCF7,  CXCR3,  
CXCR6,   CD44,   and   GZMK   were   detected   by   flow   cytometry.   Unstimulated   CD127-­
ILC1s   from   the   same   donor  were   used   for   the   control.   For   TCF7   detection,   data   are  
representative   of   8   donors;;   for   CXCR3,   CXCR6,   CD44   and   GZMK,   data   are  
representative   of   4   donors.   *Lin   denotes   the   panel   of   lineage  marker   antibodies   that  
does  not  include  anti-­CD94.    See  also  Figure  S6  and  S7.  
    
Figure   6.  WNT   Inhibition  Blocks   the  Cytokine   Induced  Transition  of  CD127-­ILC1  
into  NK  Memory  Cells  
(A-­D)  PBMCs  (A  and  B)  or  sorted  CD127-­ILC1s  (C  and  D)  were  stimulated  (Stim)  with  
IL-­12  (50  ng/ml)  and  IL-­15  (50  ng/ml)  for  16  hrs,  or  not  stimulated  (NS),  in  the  presence  
of   LGK974   (10   uM),   as   indicated.   CD94   levels   on   the   *Lin-­TBX21+   population   were  
detected   (A)  and   the   ratio  of  CD94+/CD94-­  was  calculated   (B)   (NS,  n=22;;  Stim  n=26;;  
Stim+LGK974,  n=26);;  The  percent  of  CD94  was  also  detected   (C)  and  calculated   (D)  
(n=15)  for  sorted  CD127-­ILC1s.  (E  and  F)  PBMCs  were  stimulated  with  IL-­15  (50  ng/ml)  
for  5  days,  with  or  without  LGK974  (10  uM).  The  *Lin-­CD56+  population  was  assessed  
for   CD56   and   CD94   (E),   and   the   percentage   of   CD56hi   among   *Lin-­CD56+   cells   was  
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calculated   (F)   (n=10).   (G   and   H)   PBMCs   incubated   in   the   presence   or   absence   of  
LGK974   (10   uM)   were   treated   for   16   hrs   (Pre-­stim)   with   IL-­12   (10   ng/ml),   IL-­15   (5  
ng/ml),  and  IL-­18  (50  ng/ml),  or  not  (No  pre-­stim),  and  incubated  for  5  days  in  IL-­15  (5  
ng/ml).  All  cells  were  then  stimulated  with  IL-­12  (50  ng/ml)  and  IL-­15  (50  ng/ml)  for  16  
hrs,  and  cell  associated  IFN-­γ  and  CD94  were  detected   in   the  *Lin-­TBX21+  population  
(G),   and   the   result   was   calculated   (H)   (n=13).   Each   dot   represents   a   unique   donor,  
mean   ±   s.e.m.;;   (B,   D,   F   and   H),   two-­tailed   paired   t-­test.   ∗∗∗p﹤0.001. *Lin denotes the 
panel of lineage marker antibodies that does not include anti-CD94. See also Figures 
S7.  
    
Figure  7.  HIV-­1  Infection  Increases  TCF7+NK  Cells  
(A  and  B)  TCF7   in  CD127-­ILC1s  and  CD94+NK  cells  was  detected  (A)  and  calculated  
(B)   in   PBMCs   from  HIV-­1-­   (n=21)   and  HIV-­1+   (n=11)   individuals.   (C   and  D)   The   *Lin-­
TBX21+  population  from  PBMCs  of  HIV-­1-­  (n=9)  and  HIV-­1+  (n=10)  people  was  detected  
with   NKG2C   (C)   and   results   were   calculated   (D).   (E)   Model   for   plasticity   of   CD127-­
ILC1s.  Among  ILC1s,  the  vast  majority  are  CD127-­  (left).  Inflammation  associated  with  
HIV-­1   infection   unmasks   CD127-­ILC1   plasticity   (right),   generating   increased  
percentages  of  CD94+effector  and  TCF7+memory  NK  cells.  Upon   immune  stimulation,  
memory  NK  cells  also  give  rise  to  effector  NK  cells.  Two-­tailed  unpaired  t-­test;;  mean  ±  
s.e.m.;;   ∗∗p﹤0.01, ∗∗∗p﹤0.001. *Lin denotes the panel of lineage marker antibodies that 
does not include anti-CD94.  
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